FDA Grants Accelerated Approval for INOVIO's VOCERYQ Drug
What happened
The U.S. Food and Drug Administration (FDA) granted accelerated approval for VOCERYQ, a drug developed by INOVIO, to treat adults with recurrent respiratory papillomatosis (RRP). The approval allows the drug to reduce the frequency of surgery in this population. This decision was based on a demonstrated complete response, defined as no surgical requirement within 12 months of treatment. Continued approval may require verification of clinical benefit through confirmatory studies.
From investorideas.com
Why it matters
The drug approval led to INOVIO stock becoming a top gainer on the Nasdaq. The accelerated approval for VOCERYQ signals regulatory acceptance for INOVIO's DNA medicine platform in treating HPV-related diseases.
From investorideas.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Syneos HealthSpeculative
Syneos Health might see increased service contracts due to INOVIO's higher market viability.
- AmgenSpeculative
Amgen could experience a lift in biotech sector sentiment, potentially affecting market prices.
Keep exploring
The entities involved
Related events
- FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.